#151059

Anti-RuvC [RuvC 5G9/3] mAb

Cat. #151059

Anti-RuvC [RuvC 5G9/3] mAb

Cat. #: 151059

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: RuvC

Class: Monoclonal

Application: ELISA ; RIA ; WB

Reactivity: E.coli

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Stephen West

Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-RuvC [RuvC 5G9/3] mAb
  • Research fields: Genetics
  • Clone: RuvC 5G9/3
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 79 kDa
  • Strain: Balb/c
  • Reactivity: E.coli
  • Host: Mouse
  • Application: ELISA ; RIA ; WB
  • Description: RuvC (an endonuclease) cleaves Holliday junctions.
  • Immunogen: Ruv C protein from E. Coli.
  • Isotype: IgG2b
  • Myeloma used: Sp2/0-Ag14
  • Recommended controls: LS174T, MCF-7 cells or human tonsil

Target Details

  • Target: RuvC
  • Molecular weight: 79 kDa
  • Tissue cell line specificity: LS174T, MCF-7 cells or human tonsil
  • Target background: RuvC (an endonuclease) cleaves Holliday junctions.

Applications

  • Application: ELISA ; RIA ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Davies et al. 1998. Curr Biol. 8(12):725-7. PMID: 9637927.
  • Formation of RuvABC-Holliday junction complexes in vitro.
  • Eggleston et al. 1997. Cell. 89(4):607-17. PMID: 9160752.
  • In vitro reconstitution of the late steps of genetic recombination in E. coli.